candesartan cilexetil has been researched along with Arterial Diseases, Carotid in 3 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Kino, H | 1 |
| Hama, J | 1 |
| Takenaka, T | 1 |
| Sugimura, K | 1 |
| Kamoi, K | 1 |
| Shimada, S | 1 |
| Yamamoto, Y | 1 |
| Nagata, S | 1 |
| Horiuchi, M | 1 |
| Katori, R | 1 |
| Kawamura, M | 1 |
| Terashita, Z | 1 |
| Okuda, H | 1 |
| Imura, Y | 1 |
| Shino, A | 1 |
| Nakao, M | 1 |
| Nishikawa, K | 1 |
1 trial available for candesartan cilexetil and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
2 other studies available for candesartan cilexetil and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimidazoles | 1994 |
TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
Topics: Acetylcholine; Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benz | 1993 |